ArticleJCO precision oncology2018
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.
Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).BJU international · 2026Article
- FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.Cell reports · 2026Article
- Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Observational
- SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression.Pathologica · 2025Article
- Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.Journal of the National Cancer Institute · 2024Article
- Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma.BMC cancer · 2022Article
- Race and prostate cancer: genomic landscape.Nature reviews. Urology · 2022Review
- The evolving landscape of prostate cancer somatic mutations.The Prostate · 2022Review
- Detection of disease-causing mutations in prostate cancer by NGS sequencing.Cell biology international · 2022Article
- Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.JCI insight · 2022Article
- Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.Frontiers in oncology · 2022Article
- Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer.Frontiers in genetics · 2022Article
- Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.Cell reports · 2021Article
- Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.Cancers · 2021Review
- Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.The Journal of clinical investigation · 2021Article
- Decoding the heterogeneous landscape in the development prostate cancer.Oncology letters · 2021Review
- The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.Frontiers in oncology · 2021Article
- Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.Cells · 2020Review
- Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.The Prostate · 2020Review
- SPOP and cancer: a systematic review.American journal of cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
purposeMolecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations. One of these core subtypes,
methodsWe have developed a novel gene expression signature, classifier (Subclass Predictor Based on Transcriptional Data), and decision tree to predict the
resultsThe subclass predictor based on transcriptional data model showed high sensitivity and specificity in multiple cohorts across both RNA sequencing and microarray gene expression platforms. We predicted approximately 8% to 9% of cases to be
conclusionUsing a novel gene expression model and a decision tree algorithm to define prostate cancer molecular subclasses, we found that the
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.